Broadcast Date: Friday, March 31, 2023
from 12:00 pm to 1:30 pm (ET)

Overview:

The Hatch-Waxman Act was originally designed to spur pharmaceutical innovation and increase consumer access to affordable drugs. However, given the complex nature of this law, several regulatory and patent issues have come to light, including the use of carved-out labels, or “skinny labels,” by generic drug manufacturers.

However, skinny labels could potentially induce infringement. Thus, the need for pharmaceutical companies to keep track of emerging issues and recent court rulings surrounding this evolving legal climate remains paramount.

Listen as a panel of key thought leaders and practitioners organized by The Knowledge Group provide the audience with an in-depth look at the latest developments and notable cases in the Hatch-Waxman litigation landscape. The speakers will also offer helpful insights in developing strategies to minimize risks and ensure compliance.

Key topics include:

  • Hatch-Waxman Act: An Overview
  • The GSK v. Teva Case and Other Notable Court Rulings
  • Implications of Recent Cases on the Pharmaceutical Industry
  • Skinny Labels and Patent Infringement Challenges
  • What Lies Ahead

Credit:

Course Level:

Intermediate

 

Advance Preparation:

Print and review course materials

 

Method of Presentation:

Live Webcast

 

Prerequisite: 

General knowledge of patent laws

 

Course Code:

1410566

 

NY Category of CLE Credit:

Areas of Professional Practice

 

Total Credits:

1.5 CLE

Speaker:

Jason A. Lief, Partner
Windels Marx Lane & Mittendorf, LLP

Jason Lief is a premier patent trial lawyer with 25 years of experience. He has litigated and tried dozens of major patent and other intellectual property cases on behalf of some of the world’s most innovative and dynamic companies, often involving billion-dollar products. Applying his legal and scientific training, Jason has established a reputation for winning outcomes and courtroom excellence.

Jason’s cases include major Hatch-Waxman pharmaceutical litigations (Zantac®, Wellbutrin®, Wellbutrin SR®, Wellbutrin XL®, Ceftin®, Intuniv®, Vyvanse®, Oxtellar XR®, Angiomax®, and Lialda®), as well as biotech, chemical, and consumer product patent cases. Jason has also litigated trade secret, trademark, copyright, and IP contract disputes. He has argued before the U.S. Court of Appeals for the Federal Circuit and appeared in foreign courts pursuant to the Hague Convention.  Jason has also successfully litigated in the inter partes review (IPR) arena.

Agenda:

Jason A. LiefPartner

Windels Marx Lane & Mittendorf, LLP

Date & Time:

Friday, March 31, 2023

12:00 pm to 1:30 pm (ET)

A recording will be available to view 24-48 hours after the live date.

Materials:

Coming Soon.

Please check back again later.

Who Should Attend:

  • Intellectual Property Lawyers/Counsel
  • Biotechnology/Pharmaceutical Lawyers
  • Patent Attorneys
  • Patent Licensing Attorneys
  • FDA Attorneys
  • Patent Managers
  • Patent Examiners
  • General Counsel from Biotechnology/Pharmaceutical Industries

SPEAKER

Jason A. LiefPartner
Windels Marx Lane & Mittendorf, LLP

SUBSCRIPTION PACKAGES

ALL-ACCESS PASS

View Details

CLE LAW MONTHLY

View Details

CPE FINANCE MONTHLY

View Details

Join Over 150,000 Professionals Empowering Their Careers

Learn anywhere from over 1900+ live and recorded CLE, CPE & Technology Webcasts.